// App-Quantinova.ai

301 : Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study

Researchers

Presenter

  • Paolo Ascierto

Principal Investigators

  • Karl Lewis

  • Caroline Robert

  • Daniil Stroyakovskiy

  • Helen Gogas

  • Svetlana Protsenko

  • Rodrigo Pereira

  • Thomas Eigentler

  • Piotr Rutkowski

  • Lev Demidov

  • Georgy Moiseevich Manikhas

  • Haocheng Li

  • Qian Zhu

  • Edward McKenna

  • Virginia McNally

  • Ralf Gutzmer

  • Grant McArthur

Medical Centers

  • Istituto Nazionale Tumori IRCCS, Naples, Italy

  • University of Colorado Comprehensive CC, Aurora, CO, USA

  • Gustave Roussy and Université Paris, Villejuif-Paris, France

  • Moscow City Oncology Hospital #62, Istra, Russian Federation

  • Sotiria General Hospital, Athens, Greece

  • N N Petrov National Res Center of Oncology, St Petersburg, , Russian Federation

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • University of Tubingen, Tubingen, Germany

  • Maria Sklodowska-Curie National Research, Warsaw, Poland

  • N.N. Blokhin Russian Cancer Research Center, Moscow, G Moskva, Russian Federation

  • St. Petersburg Oncology Hospital, St. Petersburg, Russian Federation

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Haut-Tumour-Zentrum Hannover (HTZH), Hannover, Germany

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Italy

  • United States

  • France

  • Russia

  • Greece

  • Brazil

  • Germany

  • Poland

  • Canada

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Cobimetinib

  • Vemurafenib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved